Paxlovid may reduce the risk of long COVID, according to a study out of the Department of Veterans Affairs. The study found that veterans who were given Paxlovid saw a 25% lower risk of developing long COVID symptoms, including heart or liver disease. (Axios)

Biogen is considering other options for CEO after leading candidate Mathai Mammen is no longer in the running. Mammen, head of R&D at Johnson & Johnson, was being considered for the role until talks between him and the company’s board broke down. (STAT News)

Viatris announced it’s planning to acquire two biotechs, Oyster Point Pharma and Family Life Sciences, for more than $700 million as it expands its ophthalmology portfolio. Oyster Point brings its FDA-approved Tyrvaya medication for dry eye disease, as well as a Phase II drug for degenerative eye disease. (Endpoints News)

Walgreens-backed VillageMD is slated to buy Summit Health in a $9 billion deal. Private equity firm Warburg Pincus-backed Summit Health runs an independent physician-run medical group and also operates urgent care clinic chain CityMD. (CNBC)

The Supreme Court rejected Bristol Myers Squibb’s bid to reinstate a $1.2 billion award linked to a patent fight with Gilead over lymphoma drug Yescarta. In 2017, Bristol Myers Squibb’s Juno Therapeutics sued Gilead’s Kite Pharma, claiming it copied technology over the drug. (Reuters)